Presentation to highlight preclinical data supporting knock down of complement factor 3, the central regulator of the complement cascade
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, announced today an upcoming presentation describing progress in its complement factor 3 (C3) program at the Ophthalmology Innovation Summit (OIS), a half-day meeting focused on the most promising and innovative treatments for retinal diseases. The summit, being held in affiliation with the American Society of Retina Specialists (ASRS), will be held in San Francisco, California, at the Marriott Marquis Hotel on Monday, August 8, 2016.
Catalyst will provide an overview of its dry age-related macular degeneration (AMD) program, including new data in non-human primate models that demonstrate knock down of C3 following a single injection of its anti-C3 protease lead candidates, significant duration of action, and encouraging safety and tolerability data.
Targeting the complement cascade is a validated approach that has shown inhibition of the progression of advanced dry AMD in early clinical studies.
“For the millions of people in the world who suffer from dry AMD, a disease that over time can cause profound vision loss, there are no approved medical treatments.” said Edwin Madison, Ph.D., Chief Scientific Officer of Catalyst. “We believe that an anti-C3 strategy may be the most efficacious and broadly applicable strategy to inhibit progression of this disease and that a protease drug may require less frequent intravitreal injections than small molecule or antibody-based therapeutic agents.”
About AMD
Age-related macular degeneration, or AMD, is the leading cause of blindness in the elderly worldwide and according to Nature, a scientific journal, affects approximately 20 million people in the United States and European Union combined. AMD is a chronic condition characterized by a progressive loss of central vision due mostly to degenerative changes and/or the formation of microvascular networks in the center of the eye’s visual field, called the macula. There are two forms of AMD, wet and dry. Wet AMD is the more severe form of the disease and represents approximately 10 percent of all AMD patients. Dry AMD is the most common form of early to intermediate stage AMD and occurs in approximately 90 percent of patients with AMD. In contrast to wet AMD, treating dry AMD remains an unmet medical need since there is no FDA-approved therapy available.
About Catalyst
Catalyst is a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions. To date, Catalyst has focused its product development efforts in the field of hemostasis, including the treatment of hemophilia and surgical bleeding, and in the field of inflammation, including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration, a condition that can cause visual impairment or blindness. Catalyst’s most advanced program is an improved next-generation coagulation Factor VIIa variant, CB 813d, which has successfully completed a Phase 1 clinical trial in severe hemophilia A and B patients. In addition to Catalyst’s lead Factor VIIa program, Catalyst has two other next-generation coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant, that is in the advanced lead stage of development. For more information, please visit www.catalystbiosciences.com.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, announced today an upcoming presentation describing progress in its complement factor 3 (C3) program at the Ophthalmology Innovation Summit (OIS), a half-day meeting focused on the most promising and innovative treatments for retinal diseases. The summit, being held in affiliation with the American Society of Retina Specialists (ASRS), will be held in San Francisco, California, at the Marriott Marquis Hotel on Monday, August 8, 2016.
Catalyst will provide an overview of its dry age-related macular degeneration (AMD) program, including new data in non-human primate models that demonstrate knock down of C3 following a single injection of its anti-C3 protease lead candidates, significant duration of action, and encouraging safety and tolerability data.
Targeting the complement cascade is a validated approach that has shown inhibition of the progression of advanced dry AMD in early clinical studies.
“For the millions of people in the world who suffer from dry AMD, a disease that over time can cause profound vision loss, there are no approved medical treatments.” said Edwin Madison, Ph.D., Chief Scientific Officer of Catalyst. “We believe that an anti-C3 strategy may be the most efficacious and broadly applicable strategy to inhibit progression of this disease and that a protease drug may require less frequent intravitreal injections than small molecule or antibody-based therapeutic agents.”
About AMD
Age-related macular degeneration, or AMD, is the leading cause of blindness in the elderly worldwide and according to Nature, a scientific journal, affects approximately 20 million people in the United States and European Union combined. AMD is a chronic condition characterized by a progressive loss of central vision due mostly to degenerative changes and/or the formation of microvascular networks in the center of the eye’s visual field, called the macula. There are two forms of AMD, wet and dry. Wet AMD is the more severe form of the disease and represents approximately 10 percent of all AMD patients. Dry AMD is the most common form of early to intermediate stage AMD and occurs in approximately 90 percent of patients with AMD. In contrast to wet AMD, treating dry AMD remains an unmet medical need since there is no FDA-approved therapy available.
About Catalyst
Catalyst is a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions. To date, Catalyst has focused its product development efforts in the field of hemostasis, including the treatment of hemophilia and surgical bleeding, and in the field of inflammation, including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration, a condition that can cause visual impairment or blindness. Catalyst’s most advanced program is an improved next-generation coagulation Factor VIIa variant, CB 813d, which has successfully completed a Phase 1 clinical trial in severe hemophilia A and B patients. In addition to Catalyst’s lead Factor VIIa program, Catalyst has two other next-generation coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant, that is in the advanced lead stage of development. For more information, please visit www.catalystbiosciences.com.
